NOVEMBER 3, 2025, Boise, IDAHO – The Fatty Liver Foundation (FLF) will have a major presence at this year’s American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (TLM) in Washington, D.C., November 7–11, 2025. FLF will introduce the inaugural cohort of Fellows of the Dr. Stephen A. Harrison Patient Advocacy Fellowship, present two scientific posters, host three Community Conversations, and participate in several sessions as part of AASLD’s Patient Programming.
The Harrison Fellows will be formally recognized during the AASLD Patient Advocate Welcome Breakfast on Friday, November 7, at 7:00 AM ET (Room 202, Level 2) as part of AASLD CEO Matthew R. D’Uva’s welcoming remarks. This marks the official public debut of the Fellowship at AASLD TLM, which honors the late Dr. Stephen A. Harrison, a pioneer in MASH clinical research and drug development, and aims to cultivate the next generation of patient advocacy leaders across the spectrum of steatotic liver disease.
“This is an extraordinary moment for the Fatty Liver Foundation,” said Wayne Eskridge, Co-Founder and CEO of FLF. “The Liver Meeting is where science, clinical innovation, and patient experience converge, and our Harrison Fellows represent the living bridge between these worlds. Their voices will help shape how liver care, research, and policy evolve in the years ahead.”
Henry E. Chang, Executive Director of FLF, added, “It’s inspiring to see our team, Harrison Fellows, and partners helping shape conversations across The Liver Meeting. The insights from FLF’s The State of Steatotic (Fatty) Liver Care in America survey reflect the real-world experiences of patients and are driving practical solutions that build trust, improve access, and make liver care more equitable for everyone.”
Jenn Jones, Founder of Sober Livers, an impact program of FLF dedicated to education and peer support for people living with metabolic dysfunction–associated alcohol-related liver disease (MetALD), alcohol-associated liver disease (ALD), and alcohol use disorder (AUD), said, “Sober Livers is about connection, understanding, and support. By bringing our community’s experiences to The Liver Meeting, we’re helping shift the conversation from stigma to recovery and showing that healing involves both the liver and the whole person.”
POSTER PRESENTATIONS
Friday, November 7, 2025 | 8:00 AM – 5:00 PM ET | Authors: 1:00 PM – 2:00 PM | Hall DE
Presenters: Jenn Jones, Neeraj Mistry, Lindsey Moore (FLF/Sober Livers)
Session: Alcohol-Associated Liver Diseases: Clinical and Experimental Presentation: Implementing a Participatory Process to Sustain Bio-Psycho-Social Support for AUD, MetALD, and ALD Patients
Publication Number: 1600
Saturday, November 8, 2025 | 8:00 AM – 5:00 PM ET | Authors: 1:00 PM – 2:00 PM | Hall DE
Presenter: Tiffany Mensah, Neeraj Mistry (FLF)
Session: MASLD/MASH – Epidemiology and Natural History, Prevention and Outcomes Presentation: Shifting Trends in U.S. Steatotic Liver Disease Care: Patient-Reported Insights from the 2022–2025 SLD Care Survey
Publication Number: 2592
COMMUNITY CONVERSATIONS
Saturday, November 8 | 1:00 – 2:00 PM ET | ZOOM ONLY
Hosted by Sober Livers
Presenter: Lindsey Moore (FLF/Sober Livers)
Title: Sober in a Not-So-Sober World: Finding Steady Ground in Unsteady Times
Description: “Sober” can mean more than life without alcohol—it can also mean approaching life with clarity, balance, and thoughtful awareness. This conversation explores the many meanings of sobriety—clarity, calm, and conscious living—and how those qualities help us navigate a world that feels increasingly loud and unsettled. Together, we’ll talk about what’s within our control, what’s not, and how to stay steady, compassionate, and connected without diving into divisive topics—focusing instead on how the world around us shapes our inner resilience.
Register: https://us02web.zoom.us/meeting/register/s49_sh31TWOuhSOUQR7Iug
Sunday, November 9 | 10:00 – 11:00 AM ET | ZOOM ONLY
Hosted by Fatty Liver Foundation
Presenters: Tiffany Mensah and Dr. Neeraj Mistry (FLF)
Title: The Bigger Picture: Insights and Support from the Steatotic Liver Disease (SLD) Community
Description: FLF’s latest survey underscores that managing SLD is not only about liver health—social determinants like transportation, finances, isolation, and mental health matter deeply. This session explores real-life challenges and the programs helping patients navigate them.
Register: https://us02web.zoom.us/webinar/register/WN_bPc7LXWuQcuhltX1HFZ1zw
Sunday, November 9 | 4:00 – 5:00 PM ET | ZOOM ONLY
Hosted by the Fatty Liver Foundation and The Liver Forum
Presenters: Henry E. Chang (FLF) and Rosemarie Sellati (Regeneron Pharmaceuticals)
Title: Integrating the Patient Voice into MASH Drug Development: PEDDLE’s Framework for a New Standard of Engagement
Description: The PEDDLE (Patient Engagement in Drug Development: Leading Through Example) Working Group—an initiative of the Liver Forum—is introducing its Patient Engagement Toolkit, a framework for integrating patient perspectives throughout MASH clinical research. The discussion will align with FDA guidance on non-invasive tests (NITs) and trial diversity efforts.
Register: https://us02web.zoom.us/webinar/register/WN_FHLtwb2VSc6geLfq21aOuA
SPEAKING HIGHLIGHTS
Friday, November 7 | 8:00 – 9:30 AM ET | Room 209, Level 2
Patient Engagement as a HABIT: Hope in Action – Breaking Barriers, Impactful Transitions
Speaker: Jenn Jones (FLF/Sober Livers)
Friday, November 7 | 2:00 – 3:00 PM ET | Room 209, Level 2
Transforming Lives in Alcohol-Associated Liver Disease: Early Detection, Equitable Treatment, and Inclusive Research Strategies
Moderator:Jenn Jones (FLF/Sober Livers)
Friday, November 7 | 4:00 – 5:30 PM ET | Room 209, Level 2
Breaking Barriers: Confronting Stigma in Liver Disease and Supporting Vulnerable Communities
Presenter: Jon E. Potter (Sober Livers)
Sunday, November 9 | 11:00 AM – 12:30 PM ET | Room 209, Level 2
Elements of Metabolic-Dysfunction-Associated Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis for Pediatric and Adult Patients
Presenters: Susan Horava and Kerry M. Sivia (FLF/Harrison Fellows)
Monday, November 10 | 2:00 – 6:00 PM ET | Marriott Marquis Ballroom Salon 1-5
Point-of-Care Liver Ultrasonography, Advanced Course
Participant: Jenn Jones (FLF/Sober Livers)
The Fatty Liver Foundation’s engagement at AASLD TLM 2025 reflects its ongoing mission to empower patients, advance early detection, and promote equitable access to care for all affected by steatotic liver disease and its related conditions.
For more information about FLF’s programs, visit www.fattyliverfoundation.org.
About the Fatty Liver Foundation
Established in 2017, the Fatty Liver Foundation (FLF) is a national non-profit organization dedicated to improving the identification, diagnosis, treatment, and support of people living with the entire spectrum of steatotic liver disease (SLD)—including metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), metabolic dysfunction–associated alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD). Through awareness, screening, education, and patient engagement, FLF works to improve outcomes for both asymptomatic and diagnosed individuals while advancing equitable access to care and early detection.
FLF also leads Sober Livers, an impact program providing education and peer support for people living with MetALD, ALD, and alcohol use disorder (AUD). Together, these initiatives embody FLF’s mission to empower patients, raise awareness, and strengthen health systems to respond to the growing epidemic of liver disease.
Connect with us at www.fattyliverfoundation.org, on Facebook (Fatty Liver Foundation JUST LIVER NEWS), LinkedIn (Fatty Liver Foundation), X/Twitter (@LiverSaver), and YouTube (Fatty Liver Foundation).
MEDIA CONTACT
Henry E. Chang
Executive Director
Fatty Liver Foundation
Email: [email protected]
Phone: +1 917 400-8900
# # #
